List view / Grid view
Drug Discovery Processes
news
Animal model of Huntington’s offers advantages for testing treatments
Using genetic engineering technology, a team of scientists have established an animal model of Huntington's disease...
news
I-BET-762 may stop cancer-causing gene in its tracks
Scientists are testing a promising drug that may stop a gene associated with obesity from triggering breast and lung cancer...
news
Programming DNA to deliver cancer drugs
New technology could lead to the development of new cancer therapies...
whitepaper
Application note: Simultaneous dual phosphoprotein target analysis with Alpha Terbium SureFire Ultra Multiplex
This application note discusses how the Alpha SureFire® Ultra™ Multiplex technology provides a phosphoprotein multiplexing detection platform that is truly homogeneous and high throughput.
article
Under the microscope: Choosing the best microplate reader
Efficient microplate readers play an important role in effective hit molecule discovery. Mark Wigglesworth, of AstraZeneca, explains what he looks for in this technology.
article
High throughput flow cytometry for multifactorial evaluation of novel therapeutic candidates using an innovative in vitro immunooncology screening platform
This recent webinar focused on the role of IntelliCyt’s iQue Screener PLUS platform as a high throughput suspension cell screening platform to facilitate simultaneous assessment of multiple parameters, while using minimal sample volumes.
article
Streamlining drug discovery assays for cancer and cardiovascular disease
Declining R&D productivity is a key challenge in the pharmaceutical industry. To increase the success rate of candidate drugs entering the clinical phase, companies must address the early stages of drug discovery.
news
Experimental obesity drug prevents development of kidney stones
Scientists have found that a drug connected with fat regulation prevents the formation of kidney stones in mice...
article
Expert view: Screening tools for better lead characterisation
Predictiveness is one of the key factors for success in the drug discovery workflow. Many compounds fail at late stages due to lack of predictive data or the discovery of unwanted side effects.
article
Informatics In-Depth Focus 2018
In this In-Depth Focus: enabling research on understudied and unstudied targets, and using multi-omics data to detail drug responses in the human metabolic network.
article
Drug Target Review – Issue #1 2018
In this issue: how customised cell engineering advances immunotherapy, how insights into auto-immunity are providing new opportunities for immune-oncology, and advances in lab automation and robotics are accelerating the pace of antimicrobial therapy.
whitepaper
Case Study: Characterisation of hiPSCs by Phenotypic Screening
Case study detailing a simple, highly reproducible phenotypic screen to characterise human induced pluripotent stem cells...
whitepaper
Application Note: Alpha Terbium SureFire Ultra Multiplex: simultaneous dual phosphoprotein target analysis
In this application note, PerkinElmer demonstrates the measurement of two phosphoprotein targets in a single sample using the Alpha Terbium SureFire Ultra kit combined with the AlphaLISA SureFire Ultra kit...
news
Antibodies provide potential targets for RSV vaccine development
Scientists have found and characterised the activity of four antibodies produced by the human immune system that targets an important protein found in the respiratory syncytial virus...
